Supporting the role of LAG-3 expressing cells contributing to the development of a permissive TME in cHL, a clinical cohort were described in which high numbers of LAG-3+ TILs within the diagnostic biopsy showed a trend for inferior outcome when treated with ABVD (Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine) chemotherapy. This evidence concerns the gene LAG3 and classic Hodgkin lymphoma.